doi: 10.1038/sj.leu.2403309.
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program
- PMID: 14961029
- DOI: 10.1038/sj.leu.2403309
Item in Clipboard
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program
Leukemia.
2004 Apr.
Free article
No abstract available
Similar articles
-
Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.Leuk Res. 2004 Jul;28(7):699-706. doi: 10.1016/j.leukres.2003.11.006. Leuk Res. 2004. PMID: 15158091
-
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.Leukemia. 2003 Dec;17(12):2318-57. doi: 10.1038/sj.leu.2403135. Leukemia. 2003. PMID: 14562125 Review.
-
Monitoring of minimal residual disease and mixed chimerism in a case of high-risk TEL/AML1+ acute lymphoblastic leukemia pre- and post-bone marrow transplantation. Czech Pediatric Haematology Working Group.Haematologica. 2000 Oct;85(10):1100-2. Haematologica. 2000. PMID: 11025608 No abstract available.
-
Detection of early precursors of t(12;21) positive pediatric acute lymphoblastic leukemia during follow-up.Pediatr Blood Cancer. 2010 Jan;54(1):158-60. doi: 10.1002/pbc.22300. Pediatr Blood Cancer. 2010. PMID: 19813247
-
Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.Br J Haematol. 1999 Apr;105(1):7-24. Br J Haematol. 1999. PMID: 10366253 Review. No abstract available.
Cited by
-
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Mol Diagn Ther. 2017 Oct;21(5):481-492. doi: 10.1007/s40291-017-0277-9. Mol Diagn Ther. 2017. PMID: 28452038 Review.
-
Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.J Mol Diagn. 2013 May;15(3):391-400. doi: 10.1016/j.jmoldx.2013.02.004. Epub 2013 Mar 27. J Mol Diagn. 2013. PMID: 23541592 Free PMC article.
-
Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.Blood Cancer J. 2011 Mar;1(3):e13. doi: 10.1038/bcj.2011.10. Epub 2011 Mar 25. Blood Cancer J. 2011. PMID: 22829126 Free PMC article.
-
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.J Mol Diagn. 2006 Jul;8(3):385-9. doi: 10.2353/jmoldx.2006.050150. J Mol Diagn. 2006. PMID: 16825513 Free PMC article.
-
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.Leukemia. 2016 Nov;30(11):2169-2178. doi: 10.1038/leu.2016.227. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
